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 Abstract: Newcastle disease virus (NDV) is one of the most important 
viral pathogens of avian species and the causative agent of atypical fowl plague, a 
highly contagious and economically important disease characterized by high 
mortality rates and reduction of egg production. The HN and F proteins are the 
main targets for immune response to NDV. Vaccination of poultry with live and 
inactivated NDV vaccines is the most effective method of control and prevention 
of Newcastle disease, however due to their disadvantages, efforts are being 
invested into developing subunit vaccines. To this end, the NDV HN and/or F 
protein have been expressed using different viruses as vectors, but have also been 
expressed using transgenic plant systems, yeast and lactic acid bacteria in order to 
produce the NDV subunit vaccine. Many authors have investigated the possibility 
of preparation of vaccines from purified and biologically active NDV subunits with 
HN and F glycoproteins, purified from nucleocapsids, viral ribonucleic acid (RNA) 
and pyrogens. The above mentioned viral glycoproteins with preserved antigenic 
structure and biological activities can be used as subunit vaccinal antigens due to 
their immunogenic properties. 
 




 Newcastle disease virus (NDV) is one of the most important viral 
pathogens of avian species and the causative agent of atypical fowl plague, a highly 
contagious and economically important disease characterized by high mortality 
rates and reduction of egg production (Westbury, 2001; Ganar et al., 2014). This is 
an enveloped virus with negative-sense single-stranded RNA and is classified in 
the genus Avulavirus of the subfamily Paramyxovirinae in the family 




Paramyxoviridae (Mayo, 2002; Kapczynski et al., 2013). The viral genome 
contains six open reading frames (ORF) which encode the nucleoprotein (NP), the 
phosphoprotein (P), the matrix protein (M), the fusion protein (F), the 
haemagglutinin-neuraminidase (HN) and the large protein (L) (Steward et al., 
1993). However, the F gene and the HN gene encodes essential proteins for 
virulence determination. The fusion (F) protein is responsible for mediating fusion 
of the viral envelope with cellular membranes while the HN protein is involved in 
cell attachment and release (Milić et al., 2001; Milić et al., 2003; Nišavić et al., 
2007; Heiden et al., 2014; Qiu et al., 2014; Jaganathan et al., 2015). The HN and 
F proteins are the main targets for immune response to NDV (Morgan et al., 1992; 
Arora et al., 2010; Chaturvedi et al., 2011; Kumar et al., 2011). Newcastle disease 
virus strains were classified according to pathotyping assays to three classes: 
virulent - velogenic, moderately virulent - mesogenic, and non-virulent – 
lentogenic virus strains (Dortmans et al., 2011; Susta et al., 2015). Lentogenic 
NDV strains sometimes cause subclinical infections with mild respiratory or 
enteric disease and are considered as low-virulent. Mesogenic NDV strains are of 
intermediate virulence causing respiratory infection with moderate mortality (< 
10%), while velogenic NDV strains are highly virulent causing mortality rates up 
to 100% (Beard and Hanson, 1981). The ND virus spreads horizontally between 
healthy and infected birds through direct contact with bodily secretions from 
infected birds (Alexander, 2009). The diagnosis of Newcastle disease virus 
infection is performed by the application of standard methods including virus 
isolation in chicken embryos, hemagglutination (HA test) and hemagglutination 
inhibition tests (HI test) as well as molecular methods based on Reverse 
transcription polymerase chain reaction - RT-PCR (Nišavić et al., 2007; Milić et 
al., 2012). 
 Vaccination of poultry with live and inactivated NDV vaccines is the most 
effective method of control and prevention of Newcastle disease (Senne et al, 
2004). However, previous experience in immunoprophylaxis of atypical fowl 
plague has shown that vaccination with both mentioned vaccine types has both 
advantages, as well as disadvantages and that routine vaccinations are insufficient 
to control this disease given the increasing number of outbreaks in commercial 
poultry flocks worldwide (Arora et al., 2010; Kang et al., 2016). Live NDV 
vaccines generally induce protective immunity in vaccinated poultry, but 
circulating live vaccine viruses present additional risks such as reversion of 
virulence and recombination with wild-type strains. Furthermore, the immune 
response of wild birds induced by infection with vaccinal strains may provide 
selective pressures resulting in viral antigenic drift or increased virulence (Lee et 
al., 2012; Palya et al., 2012; Read et al., 2015; Devlin et al., 2016). Also, vaccines 
prepared from inactivated NDV strains often have a weaker immunogenic effect in 
immunized poultry, compared to live vaccines, and can cause local inflammation 
after the application of oil-emulsion inactivated vaccines (Homhuan et al., 2004). 
 




Other types of vaccines that have been developed include the subunit and 
recombinant vaccines (Boursnell et al., 1990; Nagy et al., 1991; Peeters et al., 
2001). Another major drawback of all currently used whole-virus-based live and 
inactivated NDV vaccines is that vaccinated animals cannot be distinguished from 
infected animals with standard serological tests, such as hemagglutination 
inhibition (HI test) or virus neutralization (VN test). A different concept for the 
development of a marker vaccine is based on the use of subunit vaccines and it has 
been achieved for many antigens involved in inducing protective immunity, 
including the two glycoproteins F and HN of NDV (Morgan et al., 1992). The 
above mentioned viral glycoproteins with preserved antigenic structure and 
biological activities can be used as subunit vaccinal antigens (Milić et al., 1996; 
Tanabayashi and Compans, 1996; Milić et al., 2001; Arora et al., 2010; Milić et 
al., 2015). Furthermore, birds vaccinated with the recombinant fowlpox-NDV HN 
subunit vaccine can now be distinguished from the naturally infected ones by their 
antibody responses to the subunit vaccine on ELISA plates coated with 
recombinant baculovirus-NP protein as the coating antigen. However, such tests 
can only be useful if the current live or inactivated vaccines are replaced by 
recombinant subunit vaccines (Yusoff and Tan, 2001). 
 Theoretically, the genes encoding any protein can be cloned and expressed 
in bacteria, yeasts or mammalian cells. A number of genes encoding surface 
antigens from viruses, bacteria and other single celled pathogens have been cloned 
in expression systems and the expressed antigens have been used as vaccines 
(Arntzen and Mason, 1995). Efforts are being invested into developing subunit 
vaccines because of the disadvantages presented by the existing traditional 
vaccines. To this end, the NDV HN and/or F protein have been expressed using 
different viruses as vectors, but have also been expressed using transgenic plant 
systems, yeast and lactic acid bacteria in order to produce the NDV subunit 
vaccine. 
 As an initial approach to the development of novel anti-NDV vaccines, 
Berinstein et al. (2005) demonstrated that NDV F and HN proteins can be correctly 
expressed in transgenic potato plants. Specific anti-NDV antibodies recognize them 
and they are immunogenic in mice after parenteral administration or as edible 
vaccines, stimulating, in the latter case, the production of specific IgA in the gut. 
Shahriari et al. (2015) studied the application of tobacco hairy roots for expression 
of the F and HN epitopes of Newcastle disease virus. The authors have suggested 
that since plant-based systems possess a number of drawbacks in recombinant 
vaccine production, these might be overcome by using transient expression systems 
like tobacco hairy roots as they have proved to be an efficient tool for expression of 
these viral antigens. 
 Kang et al. (2016) demonstrated the potential of F protein of NDV 
expressed by the methylotrophic yeast Pichia pastoris (P. pastoris) as a subunit 
vaccine candidate when administered with flagellin as the adjuvant. The 
 




aforementioned protein was efficiently expressed in the P. pastoris system and 
verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis and western 
blotting. The F protein induced strong humoral and cell-mediated immune response 
in experimental mice when administered i.p. with Salmonella flagellin as adjuvant. 
Khulape et al. (2015) attempted to express the HN protein of NDV in a yeast 
expression system. The authors found that Saccharomyces cerevisiae was a better 
expression system for HN protein than Pichia pastoris as determined by codon 
usage analysis. The yeast cells were able to generate glycosylated HN protein with 
proper folding and antigenicity. The recombinant HN (rHN) protein was 
characterized by western blot and purified by affinity column purification and it 
was concluded that it could be further used as subunit vaccine. Since lactic acid 
bacteria are naturally associated with mucosal surfaces, particularly the 
gastrointestinal tract, they have also been considered as promising mucosal 
delivery vesicles to produce protective antigens (Shaw et al., 2000). Jiang et al. 
(2015) constructed a recombinant Lactobacillus plantarum (RLP) expressing HN 
protein of NDV. Oral administration of RLP significantly increased the production 
of secretory immunoglobulin A (SIgA) and the percentages of CD3+CD4+ T cells 
in chickens, providing at least partial protection in the NDV challenge experiment. 
The immunization with HN resulted in 40% survival rates in experimentally 
infected chicken. One of the possible explanations of only partial protection is that 
the selected HN protein performs less effective with regard to protection results 
compared to another glycoprotein, the fusion protein F, according to reports of 
Meulemans et al. (1986), Kumar et al., (2011) and Kim et al., (2013). 
 Recombinant vaccines based on viral coat protein subunits represent an 
efficient tool as a substitute for conventional, attenuated virus based vaccines 
(Makela, 2000). Boursnell et al. (1990) have investigated the expression of 
hemagglutinin-neuraminidase (HN) gene from the Beaudette C strain of NDV in a 
recombinant fowlpox virus vector. When the recombinant fowlpox virus was 
inoculated into chickens by intravenous or wing-web routes, specific antibodies 
against HN antigen from purified NDV virions were produced. Protective 
immunity to NDV was generated all experimental chickens and at the highest dose 
of vaccine 100% of the tested chickens were protected against challenge with a 
virulent strain of NDV. Recombinant baculoviruses containing the fusion (F) and 
hemagglutinin-neuraminidase (HN) glycoprotein gene of the viscerotropic 
velogenic (vv) NDV isolate, Kr-005/00, and a lentogenic La Sota NDV  strain were 
constructed in an attempt to develop an effective subunit vaccine to the recent 
epizootic of vvNDV in Korea (Lee et al., 2008). The authors evaluated the 
protective effect of individual recombinant glycoproteins derived from velogenic 
and lentogenic NDV strains. The recombinant glycoproteins from the virulent 
strain produced complete protection after the second immunization, whereas those 
from the lentogenic strain had a slightly lower protective effect. A synergistic 
effect of the combined F and HN glycoprotein was noted and it was concluded that 
 




the use of a subunit vaccine composed of the two glycoproteins can offer good 
protection against NDV. Ge et al. (2016) designed novel recombinant baculovirus 
vaccines expressing the NDV F or HN genes. The F-series of vaccines provided a 
greater degree of protection (87.5–100%) than the HN series (62.5–87.5%). The 
authors concluded that the baculovirus system is a promising platform for NDV 
vaccine development that combines the immunostimulatory benefits of a 
recombinant virus vector with the non-replicating benefits of a DNA vaccine. 
Kumar et al. (2011) achieved a 100% rate of protection by immunizing chickens 
using a recombinant NDV vaccine containing the F and HN gene using the avian 
paramyxovirus type III virus (APMV 3) as the 
vector. These vaccines were used to immunize 2-week-old chickens by the 
oculonasal route in order to evaluate the contribution of each protein to the 
induction of NDV-specific neutralizing antibodies and protective immunity. 
Protective immunity was evaluated by challenging the immunized birds 21 days 
later with virulent NDV and the obtained results indicated that F and HN proteins 
are independent neutralization and protective antigens, but that the contribution of 
F antigen in protection is greater. Palya et al. (2014) investigated the onset and 
long-term duration of immunity provided by a single vaccination with a turkey 
herpesvirus vector Newcastle disease (rHVT-ND) vaccine in commercial layers up 
to 72 weeks of age. Assessment of protection was done based on the prevention of 
clinical signs and reduction of challenge virus shedding via the oronasal and 
cloacal routes. Single vaccination with the rHVT-ND vaccine at one day of age 
provided complete or almost complete (95–100%) clinical protection against NDV 
challenges from 4 weeks of age up to 72 weeks of age when the latest challenge 
was done. Shedding of challenge virus both by the oronasal and cloacal route was 
significantly reduced compared to the controls. 
 Many authors have investigated the possibility of preparation of vaccines 
from purified and biologically active NDV subunits with HN and F glycoproteins, 
purified from nucleocapsids, viral ribonucleic acid (RNA) and pyrogens. The 
objective of the work of Milić et al. (2015) was to investigate some biological 
characteristics of purified glycoprotein subunits of PHY-LMV.42 Newcastle 
disease virus strain isolated from pigeons for the purpose of vaccine production. 
Testing for the immunogenicity of the viral subunits was carried out in a biological 
experiment on 75 Tetra SSL laying hens and 25 chickens Isa Brown after an 
artificial infection with Hertz 33 strain of NDV. The subunit vaccines of 256 and 
128 HAU/0.5 ml induced a protective immune response in all vaccinated animals. 
Based on the obtained results it was concluded that the examined purified viral 
subunits of the PHY-LMV.42 strain of NDV, separated from nucleocapsids (NP 
proteins with viral RNA), large polymerase protein (L) and smaller fragment of F 
protein (F2) can be used for a new potential vaccine. The study of Arora et al. 
(2010) concerned the immunization potential of purified HN and F glycoproteins 
of the Indian vaccinal NDV strain R2B. This investigation indicates the role of 
 




these glycoprotein subunits in the elicitation of protective immune response against 
NDV. Similarly, Meulemans et al. (1986) reported higher protective response of 
the F glycoprotein which could be explained by the fact that specific anti-F 




 Nowadays, the development of subunit vaccines is based on the expression 
of HN and F proteins of NDV using viruses, plant-based systems, yeast and lactic 
acid bacteria as vectors in order to prepare recombinant immunogens. Some of the 
developed vaccines stimulate a satisfactory immunological response against NDV 
and have proved to be successful in protection of vaccinated animals in challenge 
experiments. The advantage of NDV subunit vaccines comparing to live and 
inactivated vaccines is in their safety for vaccinated animals and the fact that there 
are no unwanted postvaccinal effects. The subunit vaccine production procedure 
enables the recovery of a larger concentration of vaccinal antigens, thus a greater 
number of doses of the vaccine compared to live or inactivated vaccines. Some of 
the abovementioned vaccines like VectorVax FP-N, Trovac-NDV and Innovax-ND 
have been licensed in certain countries. However, vaccinated animals may have 
acquired immunity to certain vaccinal vectors which could be unfavourable 
regarding the development of the immune response to HN and F antigens contained 
in the vaccine. Additionally, most vectors used for the preparation of subunit 
recombinant vaccines are potential pathogens for the population of vaccinated 
animals which raises the question of vaccine application in field conditions. A 
large number of NDV subunit vaccines are prepared form genetically modified live 
viruses which must pass rigorous testing before vaccine registration. Aside from 
that, the use of other expression systems like transgenic plants may cause a 
biological safety problem. Subunit NDV vaccines can also be prepared from 
purified and biologically active NDV subunits with HN and F glycoproteins, 
purified from nucleocapsids with viral ribonucleic acid (RNA) and pyrogens which 
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Virus Newcastle bolesti je jedan od najznačajnijih patogena u populaciji 
ptica i domaće živine koji izaziva atipičnu kugu živine, kontagiozno oboljenje koje 
prati visoka stopa morbiditeta i mortaliteta, što ima za posledicu i velike 
ekonomske gubitke u živinarstvu. Glikoproteinski HN i F antigeni virusa atipične 
kuge živine su najznačajniji prilikom razvoja imunološkog odgovora prijemčivih 
jedinki. Vakcinacija živine živim i inaktivisanim vakcinama protiv virusa 
Newcastle bolesti predstavlja najefikasniji metod kontrole i prevencije navedenog 
oboljenja, međutim klasične vakcine imaju izvesne nedostatke i iz tog razloga se 
sve više istraživanja se usmerava na razvoj subjediničnih vakcina. U cilju razvoja 
subjediničnih vakcina u današnje vreme se za ekspresiju HN i F proteina virusa 
Newcastle bolesti koriste različiti vektori kao što su virusi, transgene biljke, kvasci 
i mlečnokiselinske bakterije. Pored toga, mnogi autori su ispitivali mogućnosti 
pripremanja subjediničnih vakcina od prečišćenih i biološki aktivnih subjedinica, 
odnosno HN i F glikoproteina pomenutog virusa, oslobođenih od nukleokapsida sa 
virusnom ribonukleinskom kiselinom (RNK) i pirogena. Virusni glikoproteini sa 
očuvanom antigenskom strukturom i biološkim aktivnostima se zbog svojih 
imunogenih svojstava mogu koristiti kao subjedinični vakcinalni antigeni. 
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